Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and leukemia group B study 9022

Blood

Volumn 89, Issue 3, 1997, Pages 780-788

  Moore, Joseph O ^a   Dodge, Richard K ^b   Amrein, Philip C ^b   Kolitz, Jonathan ^b   Lee, Edward J ^b   Powell, Bayard ^b   Godfrey, Scott ^b   Robert, Francisco ^b   Schiffer, Charles A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZIRIDINYLBENZOQUINONE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIAZIQUONE; ETOPOSIDE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030894979     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.3.780     Document Type: Article

References (35)

1. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
2. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto (GIMEMA) Leukemia Cooperative Groups: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217, 1995
3. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glapsy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164, 1991
4. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471, 1994
5. Hoelzer D, Seipelt G: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia. Curr Opin Hematol 2:196, 1995
6. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood (in press)
7. Rowe JM, Anderson JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457, 1995
8. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA: Granulocyte-macrophage colony stimulating factor following initial chemotherapy for patients at least 60 years old with primary acute myeloid leukemia: A double-blinded, randomized study. N Engl J Med 332:1671, 1995
9. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JL, Papa G, Noens L, Ho J, O'Brien C, Matcham J, Barge A: Results of a randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukaemia. Blood 86:267a, 1995 (abstr, suppl 1)
10. Godwin JE, Kopecky KJ, Head DR, Hynes HE, Balcerzak SP, Appelbaum FR: A double blind placebo controlled trial of GCSF in elderly patients with previously untreated acute myeloid leukemia. Blood 86:434a, 1995 (abstr, suppl 1)
11. Amrein PC, Davis RB, Mayer RJ, Schiffer CA: Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB phase I study. Am J Hematol 35:80, 1990
12. Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder JN, Harden EA, Hande KR, Herzig GP: High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76:473, 1990
13. Lee EJ, Reck K, Schiffer CA: Continuous infusion diaziquone and etoposide: A phase I study in adult patients with acute leukemia. Leukemia 4:189, 1990
14. Lee EJ, Paciucci A, Amrein P, Schulman P, Davis R, Schiffer CA: A randomized phase II trial of 3 regimens in the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults: A CALGB study. Blood 76:294a, 1990
15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:626, 1985
16. Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA: Minimally differentiated acute nonlymphocytic leukemia: A distinct entity. Blood 70:1400, 1987
17. Weiss RB, Vogelzang NJ, Peterson BA, Panasci LC, Carpenter JT, Gavigan M, Sartill K, Frei E, McIntyre OR: A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. J Am Med Assoc 270:459, 1993
18. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG: Report of the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813, 1990
19. Cox DR: Regression models and life tables. J R Stat Soc B 34:187, 1972
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
22. Koziol JA, Reid N: On multiple comparisons among k samples subject to unequal patterns of censorship. Commun Statist Theor Meth A6:1149, 1977
23. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29, 1982
24. Lowenberg B, Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281, 1993
25. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871, 1990
26. Ohno R, Hiraoka A, Tanimoto M, Asou N, Kuriyama K, Kobayashi T, Yoshida M, Teshima H, Saito H, Fujimoto K: No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Blood 81:561, 1993
27. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, Maurer D, Schula G, Speiser W, Geissler K, Kier P, Hinterberger W, Lechner K: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with Standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700, 1991
28. Buchner T, Hiddemann W, Koenigsmann M, Zuhlsdorf M, Wormann B, Boekmann A, Freire EA, Innig G, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A, Schulz G: Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190, 1991
29. Estey E, Thall PF, Kantarjian HM, et al: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79:2246, 1992
30. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, Gutterman JU: Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 75:1766, 1990
31. Dombret H, Yver A, Chastang C, Degos L, the Cooperative Study Group: Increased frequency of complete remission by lenograstim recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration after intensive induction chemotherapy in elderly patients with de novo acute myeloid leukemia (AML): Final results of a randomized multicenter double-blind controlled study. N Engl J Med 332:1678, 1995
32. Zittoun R, Mandelli F, de Witte T, Willemze R, Thaler J, Hayat M, Stryckmans P, Peetermans M, Dardenne M, Solbu G, Suciu S: Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) during induction treatment of acute myelogenous leukemia (AML): A randomized trial from EORTC-GIMMEMA Leukemia Cooperative groups. Blood 84:231a, 1994 (abstr, suppl 1)
33. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Troncy J, Assouline D, Fiere D: Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine - 86 trial. J Clin Oncol 13:11, 1995
34. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
35. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ: Curative impact of intensification with high-dose cytarabine (HIDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84:111a, 1994 (abstr, suppl 1)